S1E2 - SGLT-2 Inhibitors Morning Commute: CKD Benefit in Diabetic and Non-Diabetic Patients

Visit http://morningcommutepodcast.com/SGLT2inhibitors6 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, Dr. James Januzzi and Dr. Silvio Inzucchi discuss the surge in collaboration between primary care physicians, endocrinologists, and cardiologists and the groundswell of cardiometabolic clinics. They attribute this to cardiologists moving beyond the so-called glucocentric view and focusing on how diabetes therapies might help reduce cardiovascular risk as well. Drs. Januzzi and Inzucchi will also discuss the recent guidelines that now incorporate sodium-glucose cotransporter 2 (SGLT-2) inhibitors into clinical pathways.

Visit http://morningcommutepodcast.com/SGLT2inhibitors5 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. James Januzzi and Dr. Silvio Inzucchi discuss how sodium-glucose cotransporter 2 (SGLT-2) inhibitors evolved from treatments for type 2 diabetes mellitus (T2DM) to key treatments for patients with heart failure. Drs. Januzzi and Inzucchi look at the pivotal trials that thrust these treatments into the heart failure treatment limelight.

Visit http://morningcommutepodcast.com/SGLT2inhibitors4 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. James Januzzi and Dr. Silvio Inzucchi will discuss SGLT-2 inhibition in cardiovascular risk reduction by taking a look at some of the pivotal clinical trial data.

Visit http://morningcommutepodcast.com/SGLT2inhibitors3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will focus on chronic kidney disease (CKD) in patients with or without diabetes and treatment with sodium-glucose cotransporter 2 (SGLT-2) inhibitors. The bottom line is, how should these treatments be incorporated into clinical practice?

Visit http://morningcommutepodcast.com/SGLT2inhibitors2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss clinical trial data that look at new directions for the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, particularly how they benefit patients with chronic kidney disease (CKD).

Visit http://morningcommutepodcast.com/SGLT2inhibitors1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will be discussing sodium-glucose cotransporter 2 (SGLT-2) inhibitors and their role beyond glycemic control. What are the mechanisms and renal benefit of SGLT-2 inhibitors?